Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. - Wikidata - awgldk - TriplyDB

Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.

Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.

http://www.wikidata.org/entity/Q45018087

about

Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells.Progress of molecular targeted therapies for prostate cancers Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide.Novel targeted therapeutics for metastatic castration-resistant prostate cancer.Nanoparticle technology: addressing the fundamental roadblocks to protein biomarker discovery Adaptive dose-finding studies: a review of model-guided phase I clinical trials.Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.PDGF upregulates Mcl-1 through activation of β-catenin and HIF-1α-dependent signaling in human prostate cancer cells.Targeting the PDGF signaling pathway in tumor treatment A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan.Bayesian hybrid dose-finding design in phase I oncology clinical trials.Targeted therapies for prostate cancer.Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients.Novel agents and targets in managing patients with metastatic prostate cancer.Intratumoral heterogeneity for expression of tyrosine kinase growth factor receptors in human colon cancer surgical specimens and orthotopic tumors.Nonreceptor tyrosine kinases in prostate cancer.Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer.Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.Molecular markers in prostate cancer. Part II: potential roles in management.Emerging drugs for prostate cancer.Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors.Recent developments in prostate cancer biomarker research: therapeutic implications.Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor.Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor.Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development.Bayesian nonparametric statistics: A new toolkit for discovery in cancer research.Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer.Platelet-Derived Growth Factor (PDGF)/PDGF Receptors (PDGFR) Axis as Target for Antitumor and Antiangiogenic Therapy.The stem cell factor (SCF)/c-KIT signalling in testis and prostate cancer.Small-sample behavior of novel phase I cancer trial designs.Integrating the escalation and dose expansion studies into a unified Phase I clinical trial.Docetaxel enhances the cytotoxic effects of imatinib on Philadelphia positive human chronic myeloid leukemia cells.Macromolecular dynamic contrast-enhanced (DCE)-MRI detects reduced vascular permeability in a prostate cancer bone metastasis model following anti-platelet-derived growth factor receptor (PDGFR) therapy, indicating a drop in vascular endothelial gro

P2860

Q24531982-800647A3-6088-433C-A1F0-0D6BD079CF27 Q26823014-265AC1DE-ABAF-41A8-A1F8-FFD14797D0D3 Q28082793-81FB3D22-6F29-423A-BF0A-95CC6699CCD2 Q28474977-E0388880-2016-421D-B4A4-E9E30CE2C4F2 Q33304051-47338832-8D1E-4865-BF52-0A940D5ABDAE Q33642278-5080E924-2A6B-44FD-AACA-701056189419 Q33862871-581D1267-D784-43BE-877C-788B6C321459 Q34001009-13021C49-C6CE-4841-BC19-D72BDB350EC4 Q34013882-637FBD2A-3AC1-4A55-A7A3-8805C6270D81 Q34140712-1D3AC32B-3050-4751-B318-341B0CACD19F Q34393461-86365168-8DC7-4E7B-A76B-3645E72E939A Q34683885-02E8B0FC-3859-456A-9CEC-D4135F3BC754 Q35035596-FDC927C2-ACFA-486F-BA3E-6207E55EB3FB Q35666129-E06D239E-2430-4484-8C44-6CCF35523E38 Q35776323-8A1D00AD-F20E-4D59-AECF-50F8D42684B6 Q36150842-BDF886EE-2980-4A3F-A23F-26D4CB6AFDA1 Q36166836-46D73DC4-2451-4613-9870-9DE55CCF4E18 Q36184798-D1EF97CB-104C-4B19-B6F0-168BB350B4F3 Q36555662-4CC7FB5C-7971-4372-A031-448C5818E018 Q36559630-45DD2AAC-08AF-446B-8F31-C0516884E2E3 Q36759212-311C434E-12E1-47E2-84D6-E2907949121D Q36872284-EB705801-0B34-4E8B-8496-7A0DD10555DE Q36965080-D85D8C49-8A33-4D3B-86DF-908ECCA7700C Q37109503-310AE4E8-A51B-4FF4-86B3-0C54535D33C5 Q37339702-889FBA51-5A35-41B3-9A98-E94EE1CB41FA Q37570555-51F8F086-4EFD-41D0-9E1C-4A5C14B0CCB3 Q37634058-3EDFA56D-4855-49A5-A357-7B9AE9FDD332 Q37827186-C9DB634E-683E-4843-AA82-D5A7E6C0561D Q37968256-1D6E3B28-A4CB-4E73-99AF-47F987011E3E Q38094296-A1C5302D-29D3-4A3E-AE9B-941F0FEE6550 Q38185175-46F674C8-7735-48E3-92A5-9459BD5A555B Q38262816-61647620-519A-45E9-B47A-76256BCBD6ED Q38662769-D679301A-EA36-4874-9312-D91298B5CFC6 Q38897955-699B670F-BC2B-4D13-899B-BA5633EFB05F Q38974204-06FEB01C-0A67-4B69-AA0F-3A4BA7271E5A Q39401758-0818B2B7-2B74-4D7D-849A-C6B32CA458D9 Q39479987-6D3369B0-5FAE-44E6-A747-F341A2F42354 Q39620076-71BB1B7A-0E9A-48CE-A6C0-B7BD77EAE986 Q39843822-FE172AA3-D54D-4B8F-977F-8CD604208045 Q39935853-4A92B4A9-D8E0-4964-8835-1091ED96057C

P2860

Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.

http://www.wikidata.org/entity/Q45018087

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Platelet-derived growth factor ...... n-independent prostate cancer.

@en

Platelet-derived growth factor ...... n-independent prostate cancer.

@nl

type

label

Platelet-derived growth factor ...... n-independent prostate cancer.

@en

Platelet-derived growth factor ...... n-independent prostate cancer.

@nl

prefLabel

Platelet-derived growth factor ...... n-independent prostate cancer.

@en

Platelet-derived growth factor ...... n-independent prostate cancer.

@nl

P1433

Q45018087-405FA063-EBD3-4A3D-826E-B5A7598A2850

P1476

Q45018087-78A245DA-E66F-4C05-953D-DBB2EC5B110F

P2093

Q45018087-39960797-FAD8-412E-8F0C-C840933F07A2

Q45018087-42BB874A-A007-415D-9A60-4B33FBA8FA77

Q45018087-4D9550DB-C606-4410-BB6A-F642516E42C4

Q45018087-67315ACD-D472-4B2A-999A-C4CB1F1D63B5

Q45018087-8B78AC19-0563-4562-88D8-63F584B7E071

Q45018087-91C8AAB4-F618-4F0C-BF21-A89192FB4923

Q45018087-A1AE3F35-4B19-4277-A1BA-7C1D517A6FCD

Q45018087-AC9D60B1-518C-4BE5-B5EB-AEAEC2286E6C

Q45018087-E91F99D9-3DE0-4EE5-BCFA-53E1FC5EFAE7

P304

Q45018087-B49449D6-4B55-4983-B254-6E57E1EEFC34

P31

Q45018087-2D87EBB5-FB7C-43D5-97F3-3FAD786D3D54

P356

Q45018087-5339629F-FC4B-4FAC-A160-7DC806249E3E

P407

Q45018087-4C0C6FCC-71F7-41D6-8EE3-B7A4C4622919

P433

Q45018087-FD786618-90D1-445A-9A6E-A1F412997E8C

P478

Q45018087-E388E483-A7B6-4A53-BE5E-E8BB573F1E69

P577

Q45018087-CFF17271-1CD5-4F93-9657-7D0ED6849AAC

P698

Q45018087-687DC1C6-16BA-44F0-AFB6-83CEEC98A61E

P921

Q45018087-B4BBE199-2EC6-4E10-8981-A82EF692BD61

P356

JCO.2004.10.116

P1433

Journal of Clinical Oncology

P1476

Platelet-derived growth factor ...... n-independent prostate cancer.

@en

P2093

Cherie Perez

http://www.w3.org/2001/XMLSchema#string

Christopher Logothetis

http://www.w3.org/2001/XMLSchema#string

Corazon Bucana

http://www.w3.org/2001/XMLSchema#string

Donnah Jones

http://www.w3.org/2001/XMLSchema#string

Isaiah J Fidler

http://www.w3.org/2001/XMLSchema#string

Patricia Troncoso

http://www.w3.org/2001/XMLSchema#string

Paul Mathew

http://www.w3.org/2001/XMLSchema#string

Peter F Thall

http://www.w3.org/2001/XMLSchema#string

Sun-Jin Kim

http://www.w3.org/2001/XMLSchema#string

P304

3323-3329

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2004.10.116

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2004-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15310776

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial